Inhalation Research Services wins new order worth 98,000 Euro from returning US customer
Inhalation Sciences AB (ISAB) has received a new order for an Inhalation Research Services (IRS) project using its predictive preclinical test module DissolvIt. The order follows a previous IRS DissolvIt project that, according to the client, was the first in vitro technology that enabled them to successfully predict how different Drug Candidates would perform later on in clinical trials. Predicting and preventing failure in the preclinical stage can produce enormous savings for inhaled pharmaceutical companies.The returning client is a midsize US pharma company developing inhaled therapies.